Drug Therapy and Interactions in Pediatric Oncology : a Pocket Guide.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Penteado Schmidt, Carolina Witchmichen
Otros Autores: De Menezes, Fabiana Gatti
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cham : Springer International Publishing, 2016.
Temas:
Tumors in children > Chemotherapy.
Pediatric pharmacology.
Pharmacologie pĐediatrique.
Pediatric pharmacology
Tumors in children > Chemotherapy
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Preface; Abstract; Acknowledgments, fromÈCarolina Witchmichen Penteado Schmidt; Contents; Authors; Abbreviations and Acronyms; Chapter 1: Introduction; 1.1 Childhood Cancer inËurope; 1.2 Childhood Cancer inÈNorth America; 1.3 Childhood Cancer inÈLatin America; 1.4 Childhood Cancer inÄfrica; 1.5 Childhood Cancer inÄsia; 1.6 Childhood Cancer inÈCentral America; 1.7 Childhood Cancer inÖceania; 1.8 Pharmacological Treatment inÈChildhood Cancer; Chapter 2: The Main Diseases inÈPediatric Hemato-oncology; 2.1 Hodgkin Lymphoma (HL); 2.2 Non-Hodgkin Lymphoma (NHL).
  • 2.3 Chronic Myeloid Leukemia (CML)2.4 Acute Myeloid Leukemia (AML); 2.5 Acute Lymphoblastic Leukemia (ALL); 2.6 Osteosarcoma; 2.7 Central Nervous System (CNS) Tumors; Chapter 3: The Main Protocols inÈPediatric Oncohematology; 3.1 Hodgkin Lymphoma; 3.2 Chronic Myeloid Leukemia (CML); 3.2.1 Hematological Control withḦydroxyurea; 3.2.2 Imatinib; 3.3 Acute Myeloid Leukemia (AML); 3.3.1 Protocol ofẗheÈGerman Group forÄcute Myeloid Leukemia Treatment Berlin-©Frankfurt-©MŁunster (BFM2004): Adapted fromḦEMORIO; 3.3.2 IDA-FLAG Protocol (Idarubicin, Fludarabine, Cytarabine, andÈFilgrastim).
  • 3.4 Acute Lymphoid Leukemia (ALL)3.4.1 Protocol ofÈLeukemia Treatment ofẗheÈGerman Group BerlinÈ- FrankfurtÈ- MŁunsten, ofÈ1995, forÄcute Lymphoid Leukemia (BFM95) ; 3.4.2 Therapy forÈLow-Risk Patients withẗheÈProtocol ofẗheÈBrazilian Childhood Cooperative Group ofÈ1999 (GBTLI ALL-99); 3.4.3 Protocol ofẗheÈBerlin-Frankfurt-MŁunster Group, ALL IC-BFM 2002, forÄcute Lymphoid Leukemia; 3.5 Brain Tumors; 3.5.1 High-Dose Protocol: Cyclophosphamide, Doxorubicin, andÈVincristine (HD-CAV) (Neuroblastoma) [63]; 3.5.2 Cyclophosphamide, Vincristine, Cisplatin, andËtoposide (COPE/Baby Brain I) [4].
  • 3.5.3 Eight inÖne (8 inÈ1) [4]3.5.4 Cyclophosphamide, Doxorubicin, Vincristine, Cisplatin, andËtoposide (CAV-P/VP) (Neuroblastoma) [4]; 3.6 Wilms Tumor; 3.6.1 Doxorubicin, Vincristine, andÈDactinomycin (AVD) [4]; 3.6.2 Dactinomycin andÈVincristine (AV) (Stage IV andÈFavorable Histology) [4]; 3.7 Retinoblastoma; 3.7.1 Cyclophosphamide, Cisplatin, Doxorubicin, and Etoposide (CCDE) [4]; 3.8 Non-Hodgkin Lymphoma; 3.9 High-Risk Central Nervous System B Non-Hodgkin Lymphoma andÈB Acute Lymphoblastic Leukemia: Protocol ofẗheÈFrench Society ofÈPediatric Oncology LMB86.
  • 3.10 Advanced Burkitt's Lymphoma andÄLL L3È- Protocol forÈBurkitt's Lymphoma ofẗheÈFrench Society ofÈPediatric Oncology (LMB89)3.11 Osteosarcoma; 3.11.1 High-Dose Methotrexate (HD MTX) [4]; 3.11.2 Ifosfamide, Carboplatin, andËtoposide (ICE) (for Malignant Recurrent Solid Tumors) [4]; 3.12 Hepatoblastoma; Chapter 4: Background ofÈDrug Interactions; 4.1 Basis ofÈDrug Interactions; 4.1.1 Pharmacokinetic Interactions; 4.1.2 Pharmacodynamic Interactions; 4.2 Drug: Drug Interactions; 4.2.1 Drug Interactions (Pharmacokinetics) Involving CYP450.

Ejemplares similares